Caption Management’s Epizyme, Inc EPZM Stock Holding History

Caption Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-52,500	Closed	-$436K	–	1921
2021 Q2	$436K	Buy	+52,500	New	+$443K	0.01%	1073

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Caption Management's EPZM Position: Q4 2021 in Review

Caption Management sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 44,445 shares — an estimated $228K sold.

Caption Management first reported a position in EPZM in Q2 2019 and held it in 7 quarters. The position peaked at $2.57M in Q2 2020. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

Caption Management reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
Caption Management sold 44,445 Epizyme, Inc shares in Q4 2021, an estimated $228K.
Caption Management first reported a position in Epizyme, Inc in Q2 2019 and held it in 7 quarters.
Caption Management's Epizyme, Inc position peaked at $2.57M in Q2 2020.
132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Caption Management's 13F filing for Q4 2021, filed 11 Feb 2022.